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IBS patient was 17.4 versus 10.9 for controls (p <
0.0001). The average number of prescriptions ﬁlled was
26.9 versus 19.2 for IBS patients and controls respectively 
(p < 0.0001). Medically-related work absence costs were
$301 and $176 for IBS patients and controls, respectively
(p < 0.0001).
CONCLUSIONS: IBS patients impose a signiﬁcant 
ﬁnancial burden on the employer, due to higher levels 
of medical and pharmaceutical care utilization and 
medically-related work absences compared to controls.
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OBJECTIVES: Many patients with symptoms of pouch-
itis respond to empiric antibiotic treatment. An alternate
diagnostic strategy, endoscopic evaluation reserves antibi-
otics for those patients who truly have pouchitis (approx-
imately 55% of symptomatic patients). The goal of this
project was to compare the costs and cost-effectiveness of
different strategies of diagnosis and treatment of patients
with pouchitis symptoms.
METHODS: A decision-analytic model assessed the fol-
lowing strategies: empiric treatment with metronidazole,
empiric treatment with ciproﬂoxacin, empiric treatment
with metronidazole and then ciproﬂoxacin for non-
responders, endoscopy with histology, and endoscopy
with no histology. Data regarding the likelihood of pou-
chitis, diagnostic accuracy and precision of endoscopy,
and response to empiric therapy were derived from
several recent clinical studies. Redbook wholesale prices
and 2001 Medicare reimbursement rates served as cost
source data. The model was run to determine the least
costly strategy and the most cost-effective strategy using
the number of days during the study that a patient was
diagnosed and treated as the unit of effectiveness.
RESULTS: The empiric treatment with metronidazole
strategy was the least costly ($216) strategy, followed by
the test with no histology ($228), empiric treatment with
metronidazole and then ciproﬂoxacin for non-responders
($238), empiric treatment with ciproﬂoxacin ($284), and
endoscopy with histology ($342). In cost effectiveness
analysis, the test with no histology strategy cost $12 more
and was associated with diagnosis and treatment 7 
days earlier compared with the empiric treatment with
metronidazole strategy (incremental cost effectiveness
ratio $1.83 per additional day diagnosed and treated). All
other strategies were dominated. Sensitivity analysis
revealed that results were not sensitive to variation in
model parameters.
CONCLUSION: Empiric treatment with metronidazole
was the least costly strategy, but endoscopy with no his-
tology might be considered the most cost-effective since
it offers a substantial improvement in the time to 
diagnosis and treatment for little additional cost.
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OBJECTIVES: Recent randomized trials have demon-
strated that the use of IV PPI following endoscopic
therapy lowers 30-day re-bleeding rates in patients with
ulcers displaying high-risk stigmata. However, the cost-
effectiveness of, in addition, using IV PPI routinely from
the moment of initial presentation until the endoscopy is
carried out in all bleeding patients is unknown.
METHODS: We assessed the cost-effectiveness of start-
ing an IV infusion of pantoprazole (80-mg bolus followed
by 8mg/hr) in all patients presenting with an upper GI
bleed until endoscopy can be carried out. The analysis
was conducted by creating a decision tree model in Data
3.5. Assumptions of probabilities and costs were derived
from the literature, a local Canadian cost database, 
and a national Registry of patients with Upper 
Gastrointestinal Bleeding undergoing Endoscopy
(RUGBE). Differential costs were attributed to ulcer,
variceal, and non ulcer non variceal lesions. Efﬁcacy was
the proportion of patients without an episode of re-
bleeding. Threshold and sensitivity analyses were con-
ducted. The time horizon was 30 days following hospital
admission. Costs are in 2001 Canadian dollars.
RESULTS: Using the base-case analysis, the dominant
strategy was that of IV PPI following endoscopy as it 
displayed equal effectiveness at a lesser cost (average 
cost-effectiveness of $2,743 per patient who does not re-
bleed) when compared to a strategy of starting IV PPI on
all patients pre-endoscopy. When postulating increased
beneﬁt for patients who are subsequently found to be
bleeding from high or low risk ulcer lesions, variceal, or
non variceal non ulcer causes of bleeding, the results
remain unchanged across a reasonable range of clinical
assumptions both in one-way and multi-way sensitivity
analyses.
CONCLUSIONS: The use of IV PPI following ﬁndings of
urgent endoscopy appears to be the most cost-effective
approach when compared to initiating IV PPI in all 
bleeding patients prior to endoscopy.
